Joana Goncalves - Cara Therapeutic Chief Medical Officer
| CARA Stock | USD 0.29 0.01 3.33% |
Executive
Dr. Joana Goncalves is Chief Medical Officer of the Company. Prior to joining Cara, Dr. Goncalves worked at Celgene Corporation from April 2014 to October 2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA for psoriasis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma AS, a global healthcare company specializing in dermatology and critical care, from February 2012 to April 2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa. since 2018.
| Age | 50 |
| Tenure | 6 years |
| Address | 400 Atlantic Street, Stamford, CT, United States, 06901 |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Latest Insider Transactions
Joana Goncalves Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joana Goncalves against Cara Therapeutic stock is an integral part of due diligence when investing in Cara Therapeutic. Joana Goncalves insider activity provides valuable insight into whether Cara Therapeutic is net buyers or sellers over its current business cycle. Note, Cara Therapeutic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cara Therapeutic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joana Goncalves over six months ago Disposition of 3293 shares by Joana Goncalves of Cara Therapeutic at 0.89 subject to Rule 16b-3 |
Cara Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.6343) % which means that it has lost $0.6343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8432) %, meaning that it created substantial loss on money invested by shareholders. Cara Therapeutic's management efficiency ratios could be used to measure how well Cara Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.89. The current year's Return On Capital Employed is expected to grow to -1.15. At present, Cara Therapeutic's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.6 M, whereas Non Current Assets Total are forecasted to decline to about 9.2 M.Similar Executives
| Found 8 records | EXECUTIVE Age | ||
| Matthew Kreps | 22nd Century Group | N/A | |
| Steven Przybyla | 22nd Century Group | N/A | |
| Scott Marion | 22nd Century Group | N/A | |
| Robert Manfredonia | 22nd Century Group | 59 | |
| Christina Bertsch | Corbus Pharmaceuticals Holding | N/A | |
| Daniel Otto | 22nd Century Group | 34 | |
| MD MA | Corbus Pharmaceuticals Holding | 50 | |
| Jonathan Staffeldt | 22nd Century Group | 42 | |
Management Performance
| Return On Equity | -1.84 | ||||
| Return On Asset | -0.63 |
Cara Therapeutic Leadership Team
Elected by the shareholders, the Cara Therapeutic's board of directors comprises two types of representatives: Cara Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutic's management team and ensure that shareholders' interests are well served. Cara Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joana Goncalves, Chief Medical Officer | ||
| Christopher Posner, CEO President | ||
| Beth Weinberg, VP QA | ||
| Joana MD, Chief Officer | ||
| Eric Vandal, Senior Commercial | ||
| Frdrique Menzaghi, Chief RD | ||
| Iris Francesconi, Chief Relations | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer | ||
| Matthew Murphy, Manager Relations | ||
| Beth RPh, Senior QA |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.84 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (16.36) % | ||||
| Current Valuation | (22.71 M) | ||||
| Shares Outstanding | 54.86 M | ||||
| Shares Owned By Insiders | 15.73 % | ||||
| Shares Owned By Institutions | 28.15 % | ||||
| Number Of Shares Shorted | 942.53 K | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 22.50 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.